Insulet Corporation
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$33.6M
Doctors Paid
14,420
Transactions
90,374
2024 Total
$7.2M
Payment Breakdown by Category
Research$19.2M (57.2%)
Food & Beverage$1.7M (5.2%)
Consulting$204,161 (0.6%)
Travel$162,113 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $19.2M | 819 | 57.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $11.5M | 7,348 | 34.1% |
| Food and Beverage | $1.7M | 80,170 | 5.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $567,403 | 481 | 1.7% |
| Consulting Fee | $204,161 | 107 | 0.6% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $162,830 | 96 | 0.5% |
| Travel and Lodging | $162,113 | 1,201 | 0.5% |
| Education | $35,302 | 43 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $21,664 | 19 | 0.1% |
| Grant | $12,000 | 2 | 0.0% |
| Gift | $2,010 | 88 | 0.0% |
Payments by Type
Research
$19.2M
819 transactions
General
$14.4M
89,555 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Evaluating the Safety and Effectiveness of the Omnipod Horizon Automated Glucose Control System in Patients with Type 1 Diabetes | $2.8M | 1 | 78 |
| Safety and Efficacy of the Omnipod 5 Automated Insulin Delivery System in Adults with Type 2 Diabetes. | $1.9M | 0 | 42 |
| Evaluating the Safety and Effectiveness of the Omnipod HorizonAutomated Insulin Delivery System in Patients with Type 1 Diabetes | $1.6M | 0 | 72 |
| Safety and Efficacy of the Omnipod 5 Automated Insulin Delivery System in Adults with Type 2 Diabetes | $1.4M | 0 | 77 |
| Evaluating the Safety and Effectiveness of the Omnipod HorizonAutomated Glucose Control System in Children with Type 1 Diabetes Aged 2.0-5.9 Years: Preschool Cohort | $1.3M | 0 | 36 |
| Safety and Efficacy of the OmnipodTM 5 Automated Insulin Delivery Systemin Adults with Type 2 Diabetes | $1.2M | 0 | 130 |
| Evaluating the safety and effectiveness of the Omnipod 5 Automated Insulin Delivery System in patients with type 2 diabetes | $1.2M | 0 | 89 |
| Evaluating glucose control in patients with type 1 diabetes under free-living conditions with the Insulet automated glucose control system: IDE3 | $763,615 | 0 | 16 |
| Evaluating the safety and effectiveness of the Omnipod 5 AutomatedInsulin Delivery System in patients with type 2 diabetes | $678,674 | 0 | 31 |
| Evaluating the Safety and Effectiveness of the Omnipod Horizon Automated Insulin Delivery System in Children with Type 1 Diabetes Aged 2.0-5.9 Years: Preschool | $607,306 | 0 | 39 |
| AP IDE #3 | $507,135 | 0 | 13 |
| AP-IDE #1 | $428,364 | 0 | 6 |
| Evaluating the Safety and Effectiveness of the Omnipod Horizon Automated Glucose Control System in Children with Type 1 Diabetes Aged 2.0-5.9 Years: Preschool Cohort | $413,091 | 0 | 8 |
| Evaluating the Saftey and Effectiveness of the Omnipod Horizon Automated Glucose Control System in patients with Type 1 Diabetes | $352,960 | 0 | 13 |
| Safety and Efficacy of the Omnipod 5 Automated Insulin Delivery Systemin Adults with Type 2 Diabetes | $332,831 | 0 | 37 |
| Evaluating the Safety and Effectiveness of the Omnipod Horizon Automated Insulin Delivery System in Patients with Type 1 Diabetes | $322,717 | 0 | 7 |
| Safety and Efficacy of the OmnipodTM 5 Automated Insulin Delivery System in Adults with Type 2 Diabetes | $311,624 | 0 | 16 |
| Prepivotal Evaluation of the Safety and Effectiveness of the Omnipod Horizon Automated Glucose Control System in Patients with Type 1 Diabetes | $292,005 | 1 | 7 |
| Evaluating the safety and efficacy of the Omnipod 5 System use compared to pump therapy in the treatment of Type 1 diabetes: a randomized, parallel-group clinical trial | $290,186 | 0 | 15 |
| Evaluating the Safety and Effectiveness of the Omnipod 5 System Compared to Pump Therapy in the Treatment of Type 1 Diabetes: a Randomized, Parallel-Group Clinical Trial | $252,264 | 0 | 3 |
| Evaluating the Safety and Effectiveness of the Omnipod 5 AutomatedInsulin Delivery System in Patients with Type 2 Diabetes | $246,601 | 0 | 10 |
| AP-IDE #3 | $221,620 | 0 | 3 |
| AP IDE #1 | $193,770 | 0 | 4 |
| Evaluating the Safety and Effectiveness of the OmnipodHorizon Automated Insulin Delivery System in Patientswith Type 1 Diabetes | $166,132 | 0 | 12 |
| Safety and efficacy of the Omnipod 5 System use compared to pump therapy in the treatment of Type 1 diabetes: a randomized, parallel-group clinical trial | $164,228 | 0 | 1 |
| Effectiveness of the Omnipod Insulin Management System on Glycemic Control in Adult Patients with Type 1 and Type 2 Diabetes Previously treated with Multiple Daily Injections or Continuous Subcutaneous Insulin Infusion | $144,510 | 0 | 3 |
| EVALUATING THE SAFETY AND EFFECTIVENESS OF THE OMNIPOD HORIZONAUTOMATED INSULIN DELIVERY SYSTEM IN PATIENTS WITH TYPE 1 DIABETES | $143,636 | 0 | 1 |
| Evaluating the Safety and Effectiveness of the Omnipod Horizon Automated Glucose Control System in Children with Type 1 Diabetes Aged 2.0-5.9 Years: Preschool Cohort, | $102,057 | 0 | 11 |
| AP IDE #2 | $100,246 | 0 | 1 |
| Efficacy and Safety of the Omnipod 5 System Compared to Pump Therapy in the Treatment ofType 1 Diabetes: a Randomized, Parallel-Group Clinical Trial | $97,577 | 0 | 3 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2019 |
|---|---|---|---|---|
| Dr. John Fallon, M.d, M.D | Internal Medicine | Boston, MA | $2.3M | $0 |
| Wayne Frederick, Md, MD | Surgical Oncology | Washington, DC | $729,243 | $0 |
| Luciana Borio, M.d, M.D | Infectious Disease | Baltimore, MD | $579,705 | $0 |
| Anita Swamy, M.d, M.D | Pediatric Endocrinology | Chicago, IL | $273,823 | $0 |
| Dr. Isaiah Pittman, Md, MD | Endocrinology, Diabetes & Metabolism | Terre Haute, IN | $144,690 | $0 |
| Hisham Alrefai, Md, MD | Internal Medicine | Louisville, KY | $121,124 | $0 |
| Melissa Stembridge, Fnp, FNP | Family | Quincy, IL | $114,202 | $0 |
| Michelle Dart, Pnp, PNP | Nurse Practitioner | Syracuse, NY | $94,552 | $0 |
| Mrs. Martha Carranza, Np, NP | Family | Mission Viejo, CA | $81,525 | $0 |
| Pablo Mora, Md, MD | Internal Medicine | Plano, TX | $72,812 | $0 |
| Hector Granados, Md, MD | Pediatrics | El Paso, TX | $65,055 | $0 |
| Erin Henry, Np, NP | Family | Lawrenceville, GA | $61,588 | $0 |
| Erin Martin, Aprn, APRN | Family | Norwalk, CT | $54,735 | $0 |
| Sue Rankin, Np, NP | Nurse Practitioner | Amarillo, TX | $47,754 | $0 |
| Dr. Gregory Forlenza, Md, MD | Pediatric Endocrinology | Aurora, CO | $46,697 | $0 |
| Marina Charitou, Md, MD | Endocrinology, Diabetes & Metabolism | East Setauket, NY | $46,285 | $0 |
| Mrs. Carol Holland, Cfnp, CFNP | Family | Roswell, NM | $45,329 | $0 |
| Dr. Eden Miller, D.o, D.O | Obesity Medicine | Bend, OR | $41,188 | $0 |
| Dr. Martin Sarkar, D.o, D.O | Endocrinology, Diabetes & Metabolism | Frederick, MD | $40,263 | $0 |
| Dr. Thomas O'connell, Md, MD | Endocrinology, Diabetes & Metabolism | Burlington, NC | $39,917 | $0 |
| Jessica Goettl, Aprn, APRN | Primary Care | Louisville, KY | $39,773 | $0 |
| Allison Hitt, Arpn, ARPN | Family | Manila, AR | $38,358 | $0 |
| Dr. Ania Janicka, D.o, D.O | Endocrinology, Diabetes & Metabolism | Hudson, FL | $36,116 | $0 |
| Mrs. Marta Eule, Aprn, APRN | Family | Port St Lucie, FL | $34,449 | $0 |
| Mrs. Julie Taylor, Ms-Fnp, MS-FNP | Family | Fort Worth, TX | $33,601 | $0 |
About Insulet Corporation
Insulet Corporation has made $33.6M in payments to 14,420 healthcare providers, recorded across 90,374 transactions in the CMS Open Payments database. In 2024, the company paid $7.2M. The top product by payment volume is Omnipod ($26.8M).
Payments were distributed across 163 medical specialties. The top specialty by payment amount is Internal Medicine ($2.9M to 2,288 doctors).
Payment categories include: Food & Beverage ($1.7M), Consulting ($204,161), Research ($19.2M), Travel & Lodging ($162,113).
Insulet Corporation is associated with 3 products in the CMS Open Payments database.